You are here: Industry Insights > Market News > Morocco’s Sothema to produce China’s Sinopharm vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Morocco’s Sothema to produce China’s Sinopharm vaccine

firstwordpharmaJuly 06, 2021

Tag: Sothema , COVID-19 , Vaccine

Favorites

Moroccan pharmaceutical firm Sothema will soon start producing 5 million doses of Sinopharm's COVID-19 vaccine in the North African country, as reported in Yahoo!News.

Morocco’s Sothema to produce China’s Sinopharm vaccine

The Moroccan government also signed a deal with Sweden’s Recipharm to set up a plant in Morocco to produce other key vaccines.

The news source said Morocco, which rolled out a COVID-19 vaccination campaign in January, has inoculated more people against the virus than other African countries.

It had administered 19.2 million doses of the Sinopharm and AstraZeneca vaccines as of July 5.

Previous:Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Next:Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Morocco’s Sothema to produce China’s Sinopharm vaccine | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

Morocco’s Sothema to produce China’s Sinopharm vaccine

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may like
More>>

Morocco’s Sothema to produce China’s Sinopharm vaccine

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>